Vincent Enouf
Overview
Explore the profile of Vincent Enouf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
4406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abou Chakra C, Blanquart F, Vieillefond V, Enouf V, Visseaux B, Haim-Boukobza S, et al.
Emerg Microbes Infect
. 2025 Mar;
:2466699.
PMID: 40071892
Background: The epidemiology of respiratory viruses and vaccine effectiveness (VE) in the community is not well described. This study assessed VE against a positive test of influenza (VEf) and SARS-CoV-2...
2.
Blanquart F, Vieillefond V, Visseaux B, Abou Chakra C, Nunes M, Jacques A, et al.
Euro Surveill
. 2025 Feb;
30(7).
PMID: 39980426
Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine...
3.
Traore A, Charniga K, Grellet S, Terpant G, Da Cruz H, Lamy A, et al.
Euro Surveill
. 2025 Jan;
30(1.
PMID: 39790077
BackgroundEarly detection and characterisation of SARS-CoV-2 variants have been and continue to be essential for assessing their public health impact. In August 2023, Santé publique France implemented enhanced surveillance for...
4.
Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, et al.
Pathog Immun
. 2024 Oct;
10(1):1-11.
PMID: 39391808
Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel...
5.
Inizan C, Courtot A, Sturmach C, Griffon A, Biron A, Bruel T, et al.
PLoS Med
. 2024 Sep;
21(9):e1004397.
PMID: 39325828
Background: Pacific Islanders are underrepresented in vaccine efficacy trials. Few studies describe their immune response to COVID-19 vaccination. Yet, this characterization is crucial to re-enforce vaccination strategies adapted to Pacific...
6.
Brault A, Pontais I, Enouf V, Debeuret C, Bloch E, Paireau J, et al.
Lancet Child Adolesc Health
. 2024 Aug;
8(10):721-729.
PMID: 39208833
Background: Respiratory syncytial virus (RSV) is a major cause of hospitalisations and deaths among infants worldwide. France was one of the first countries to implement a national programme (beginning on...
7.
Laniece Delaunay C, Mazagatos C, Martinez-Baz I, Turi G, Goerlitz L, Domegan L, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2419258.
PMID: 38949812
Importance: In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns. Objective: To estimate...
8.
Gressens S, Enouf V, Creon A, Melica G, Lemonnier F, Dupuis J, et al.
Int J Infect Dis
. 2024 May;
146:107108.
PMID: 38795841
Objectives: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment. We aimed to assess humoral responses to boosted influenza vaccination...
9.
Laniece Delaunay C, Martinez-Baz I, Seve N, Domegan L, Mazagatos C, Buda S, et al.
Euro Surveill
. 2024 Mar;
29(13).
PMID: 38551095
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic...
10.
Maurel M, Howard J, Kissling E, Pozo F, Perez-Gimeno G, Buda S, et al.
Euro Surveill
. 2024 Feb;
29(8).
PMID: 38390651
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering...